Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.

Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:

Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism

Showing studies that mention “ovarian rhabdomyosarcoma”.

Human onlyPositive outcomesSafety signalsTrials2 of 4 studies

Case reportInconclusiveLimited evidenceTier 3 · early humann = 1

Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor

Journal of cancer research and therapeutics · Oct 2025 · case report

Cyclophosphamide Actinomycin-d Vincristineovarian rhabdomyosarcoma

This case report describes a 17-year-old girl with a very rare ovarian rhabdomyosarcoma. The tumor was diagnosed by imaging, pathology, and immunohistochemistry, and it came back within 3 months after surgery. The authors report that she then received VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide), and they emphasize the need for earlier diagnosis and more standardized treatment approaches.

Studied with: vincristine, actinomycin D, cyclophosphamide.

Key findings

Imaging showed a large solid-cystic pelvic mass.
Histopathology and immunohistochemical markers (desmin, myogenin, WT1) confirmed ovarian rhabdomyosarcoma.
Recurrence occurred within 3 months after surgical resection.
VAC chemotherapy was given after early relapse.

Limitations: Single-patient case report.; No control group.; No quantitative treatment outcome data reported.; Cannot determine effectiveness of VAC from this report alone.; Focus is diagnostic and descriptive rather than evaluative..

Describes a rare ovarian cancer case and subsequent chemotherapy, but does not evaluate a compound's anticancer effect in a comparative way.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportTrialReported positiveLimited evidenceTier 3 · early humann = 2

Primary ovarian rhabdomyosarcoma in children

Pediatric surgery international · May 2008 · case reports

Cyclophosphamide Vincristine Doxorubicinovarian rhabdomyosarcomaalveolar rhabdomyosarcomaembryonal rhabdomyosarcoma

This report describes two children with very rare primary ovarian rhabdomyosarcoma. After complete surgical removal, both received chemotherapy with vincristine, doxorubicin, and cyclophosphamide and had a good response. Both patients were alive 8 and 9 months after surgery.

Key findings

Two pediatric cases of primary ovarian rhabdomyosarcoma were described.
Both patients underwent complete resection of the primary tumor.
Both received vincristine, doxorubicin, and cyclophosphamide chemotherapy.
The abstract reports a good response to therapy and survival at 8 and 9 months post-operatively.

Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..

Describes management of a rare ovarian cancer in children, including chemotherapy, but does not isolate the effect of any single compound.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed